Nanomerics is pleased to announce a major milestone in toxicology testing of its Molecular Envelope Technology has been completed.
GLP testing on the MET has been completed for the repeat administration of the MET via the oral and intranasal routes and significantly high No Observed Adverse Effect Levels (NOAELs) have been documented by prestigious external contract research organisations. The toxicology tests were conducted in two major tranches of activity and include safety pharmacology tests on the central nervous and respiratory systems as well as repeat dose 28 day toxicology tests in two species.
Nanomerics is pleased to announce that the NOAELs are orders of magnitude above the predicted clinical doses of the MET and thus no toxicology issues have been identified that preclude the use of Nanomerics’ MET in clinical studies. Nanomerics’ Chief Executive Officer, Professor Andreas G. Schatzlein, says, “we are delighted that these regulatory toxicology screens have been completed and we look forward to advancing our internal assets to the the clinical stage of their development. These study results also allow us to interact meaningfully with our numerous customers and move external assets to clinical testing."